Dynamic Technology Lab Private Ltd lifted its holdings in Novanta Inc. (NASDAQ:NOVT – Free Report) by 94.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,696 shares of the technology company’s stock after buying an additional 5,666 shares during the quarter. Dynamic Technology Lab Private Ltd’s holdings in Novanta were worth $1,171,000 as of its most recent SEC filing.
Other institutional investors also recently modified their holdings of the company. Pilgrim Partners Asia Pte Ltd bought a new stake in Novanta during the third quarter worth about $36,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Novanta in the third quarter worth about $40,000. Huntington National Bank increased its stake in shares of Novanta by 65.7% during the second quarter. Huntington National Bank now owns 492 shares of the technology company’s stock valued at $63,000 after purchasing an additional 195 shares in the last quarter. Harbor Investment Advisory LLC increased its stake in shares of Novanta by 47.1% during the third quarter. Harbor Investment Advisory LLC now owns 987 shares of the technology company’s stock valued at $99,000 after purchasing an additional 316 shares in the last quarter. Finally, Blueshift Asset Management LLC purchased a new position in shares of Novanta during the second quarter valued at approximately $213,000. 98.35% of the stock is currently owned by institutional investors.
Novanta Stock Down 3.9%
NASDAQ:NOVT opened at $131.22 on Monday. The firm has a market cap of $4.68 billion, a P/E ratio of 89.88 and a beta of 1.61. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.80 and a current ratio of 3.69. Novanta Inc. has a fifty-two week low of $98.27 and a fifty-two week high of $149.95. The firm has a 50-day simple moving average of $134.88 and a two-hundred day simple moving average of $121.05.
Insider Buying and Selling
In other Novanta news, CFO Robert Buckley sold 1,423 shares of Novanta stock in a transaction on Friday, February 20th. The stock was sold at an average price of $140.88, for a total value of $200,472.24. Following the completion of the sale, the chief financial officer owned 93,814 shares of the company’s stock, valued at approximately $13,216,516.32. This trade represents a 1.49% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Matthijs Glastra sold 7,500 shares of Novanta stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $145.04, for a total value of $1,087,800.00. Following the completion of the sale, the chief executive officer directly owned 57,367 shares of the company’s stock, valued at approximately $8,320,509.68. The trade was a 11.56% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 24,346 shares of company stock valued at $3,382,737. 1.20% of the stock is owned by company insiders.
Analyst Ratings Changes
NOVT has been the topic of a number of analyst reports. Robert W. Baird set a $150.00 price target on Novanta in a research report on Wednesday, February 25th. Zacks Research raised Novanta from a “strong sell” rating to a “hold” rating in a research report on Friday, January 16th. Finally, Weiss Ratings upgraded Novanta from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 20th. Three equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $150.00.
Read Our Latest Report on Novanta
About Novanta
Novanta, Inc (NASDAQ: NOVT) is a global technology company that designs and manufactures precision components, subsystems and software used in advanced photonics and motion control applications. The company serves customers in the medical device and advanced industrial markets, supplying critical technologies for diagnostics and therapeutic systems, semiconductor and electronics manufacturing, and scientific instrumentation. Novanta’s product portfolio includes laser control modules, optics, beam delivery systems, high-precision motors, actuators, stages, and fluidics solutions designed to meet stringent accuracy and reliability requirements.
Novanta’s Photonics segment delivers laser and energy delivery components that enable minimally invasive surgical procedures and diagnostic imaging.
See Also
- Five stocks we like better than Novanta
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- What a Former CIA Agent Knows About the Coming Collapse
- Elon Musk already made me a “wealthy man”
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
Want to see what other hedge funds are holding NOVT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novanta Inc. (NASDAQ:NOVT – Free Report).
Receive News & Ratings for Novanta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novanta and related companies with MarketBeat.com's FREE daily email newsletter.
